Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 22 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 1 page · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a notification regarding a recent USFDA inspection at its API site in Changodar, Ahmedabad. The inspection, which took place over several days, resulted in six observations, none of which were related to data integrity. The company has four Drug Master Files under approval with the USFDA and plans to address the observations noted during the inspection. This disclosure is made in accordance with regulatory requirements for transparency to investors and the exchange.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases